Thomas Morris

2.3k citations

59 papers · 1.6k indexed · h-index 23

Impact in

Pulmonary and Respiratory Medicine top 2%
- Prostate Cancer Treatment and Research
- Prostate Cancer Diagnosis and Treatment
Endocrinology, Diabetes and Metabolism top 5%
- Hormonal and reproductive studies

Papers in ⓘ

Pulmonary and Respiratory Medicine 38
- Prostate Cancer Treatment and Research 35
- Prostate Cancer Diagnosis and Treatment 13
Oncology 19
- Bone health and treatments 9
- Cancer Treatment and Pharmacology 5

Co-authors: Peter Iversen (14 shared papers)J. Armstrong (8 shared papers)Manfred P. Wirth (8 shared papers)David G. McLeod (5 shared papers)William A. See (5 shared papers)Stuart McIntosh (4 shared papers)Kristine Pemberton (4 shared papers)Karim Fizazi (4 shared papers)
Journals: Prostate Cancer and Prostatic Diseases (5 papers)Journal of Clinical Oncology (5 papers)British Journal of Urology (5 papers)European Urology (4 papers)Cancer Chemotherapy and Pharmacology (2 papers)
Partner nations: United Kingdom United States Denmark

In The Last Decade

Thomas Morris

59 papers receiving 1.6k citations

Peers

Countries citing papers authored by Thomas Morris

Since Specialization

Citations

This map shows the geographic impact of Thomas Morris's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Thomas Morris with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Thomas Morris more than expected).

Fields of papers citing papers by Thomas Morris

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Thomas Morris. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Thomas Morris. The network helps show where Thomas Morris may publish in the future.

Co-authors

The 25 scholars most cited alongside Thomas Morris, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Thomas Morris Line = papers co-authored together Thomas Morris links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Showing the 20 most-cited of 59 papers — load more, or switch the sort, to bring in the rest.

#	Work
1	Bicalutamide 150 mg plus standard care vs standard care alone for early prostate cancer British Journal of Urology ·David G. McLeod, Peter Iversen, William A. See, Thomas Morris, J. Armstrong, Manfred P. Wirth, (unknown)	2005	196
2	Phase III, Randomized, Placebo-Controlled Study of Docetaxel in Combination With Zibotentan in Patients With Metastatic Castration-Resistant Prostate Cancer Journal of Clinical Oncology ·Karim Fizazi, Celestia S. Higano, Joel B. Nelson, Martin Gleave, Kurt Miller, Thomas Morris, Faith E. Nathan, Stuart McIntosh, Kristine Pemberton, Judd W. Moul	2013	148
3	Safety and Efficacy of the Specific Endothelin-A Receptor Antagonist ZD4054 in Patients with Hormone-Resistant Prostate Cancer and Bone Metastases Who Were Pain Free or Mildly Symptomatic: A Double-Blind, Placebo-Controlled, Randomised, Phase 2 Trial European Urology ·Nicholas D. James, Armelle Caty, Michael Borre, Bernard A. Zonnenberg, Philippe Beuzeboc, Thomas Morris, De Phung, Nancy A. Dawson	2008	137
4	Phase 3, randomized, placebo‐controlled study of zibotentan (ZD4054) in patients with castration‐resistant prostate cancer metastatic to bone Cancer ·Joel B. Nelson, Karim Fizazi, Kurt Miller, Celestia S. Higano, Judd W. Moul, Hideyuki Akaza, Thomas Morris, Stuart McIntosh, Kristine Pemberton, Martin Gleave	2012	91
5	Final safety and efficacy analysis of the specific endothelin A receptor antagonist zibotentan (ZD4054) in patients with metastatic castration‐resistant prostate cancer and bone metastases who were pain‐free or mildly symptomatic for pain: a double‐blind, placebo‐controlled, randomized Phase II trial British Journal of Urology ·Nicholas D. James, Armelle Caty, Heather Payne, Michael Borre, Bernard A. Zonnenberg, Philippe Beuzeboc, Stuart McIntosh, Thomas Morris, De Phung, Nancy A. Dawson	2010	88
6	Antiandrogen monotherapy in patients with localized or locally advanced prostate cancer: final results from the bicalutamide Early Prostate Cancer programme at a median follow‐up of 9.7 years British Journal of Urology ·Peter Iversen, David G. McLeod, William A. See, Thomas Morris, J. Armstrong, Manfred P. Wirth, (unknown)	2010	78
7	Phase III, randomized, placebo-controlled study of once-daily oral zibotentan (ZD4054) in patients with non-metastatic castration-resistant prostate cancer Prostate Cancer and Prostatic Diseases ·K. Miller, Judd W. Moul, Martin Gleave, Karim Fizazi, James B. Nelson, Thomas Morris, Faith E. Nathan, Stuart McIntosh, Kristine Pemberton, Celestia S. Higano	2013	64
8	Androgen Deprivation Therapy and the Risk of Coronary Heart Disease and Heart Failure in Patients with Prostate Cancer Drug Safety ·Elisa Martín‐Merino, Saga Johansson, Thomas Morris, Luis A. Garcı́a Rodrı́guez	2011	61
9	Prevention and management of bicalutamide-induced gynecomastia and breast pain: randomized endocrinologic and clinical studies with tamoxifen and anastrozole Prostate Cancer and Prostatic Diseases ·Daniel R. Saltzstein, Paul Sieber, Thomas Morris, J.L. Gallo	2005	58
10	Bicalutamide (Casodex) 150 mg as immediate therapy in patients with localized or locally advanced prostate cancer significantly reduces the risk of disease progression Urology ·Manfred P. Wirth, C. Tyrrell, Michael B. Wallace, K.P.J. Delaere, Manuel Sánchez‐Chapado, J. Ramon, John Hetherington, Francisco Pina, C.F. Heynes, Torsten Börchers, Thomas Morris, A Stone	2001	57
11	Assessment of treatment response in tuberculosis Expert Review of Respiratory Medicine ·Neesha Rockwood, Elsa Du Bruyn, Thomas Morris, Robert J. Wilkinson	2016	53
12	Inguinal hernia in Stage M0 prostate cancer: A comparison of incidence in men treated with and without radical retropubic prostatectomy—an analysis of 1105 patients Urology ·Johan Stranne, Jonas Hugosson, Peter Iversen, Thomas Morris, Pär Lodding	2005	41
13	Efficacy and Tolerability of Radiotherapy as Treatment for Bicalutamide-induced Gynaecomastia and Breast Pain in Prostate Cancer European Urology ·Hendrik Van Poppel, C. Tyrrell, Karin Haustermans, P. Van Cangh, F. Keuppens, P Colombeau, Thomas Morris, Louise Garside	2004	40
14	Tamoxifen as Prophylaxis for Prevention of Gynaecomastia and Breast Pain Associated with Bicalutamide 150mg Monotherapy in Patients with Prostate Cancer: A Randomised, Placebo-Controlled, Dose–Response Study European Urology ·Yves Fradet, Blair Egerdie, Morten Andersen, Teuvo L.J. Tammela, Mahmoud Nachabé, J. Armstrong, Thomas Morris, Sunil Navani	2007	38
15	Is there a role for antiandrogen monotherapy in patients with metastatic prostate cancer? Prostate Cancer and Prostatic Diseases ·AV Kaisary, Peter Iversen, CJ Tyrrell, Kevin Carroll, Thomas Morris	2001	30
16	Bicalutamide 150 mg in addition to standard care for patients with early non-metastatic prostate cancer Updated results from the Scandinavian Prostate Cancer Period Group-6 Study after a median follow-up period of 7.1 years Scandinavian Journal of Urology and Nephrology ·Peter Iversen, Jan‐Erik Johansson, Pär Lodding, Timo Kylmälä, P.I. Lundmo, Peter Klarskov, Teuvo L.J. Tammela, İlker Taşdemir, Thomas Morris, J. Armstrong, (unknown)	2006	28
17	Pharmacokinetics and tolerability of zibotentan (ZD4054) in subjects with hepatic or renal impairment: two open-label comparative studies PubMed ·Helen Tomkinson, John Kemp, Stuart Oliver, Helen Swaisland, Maria Taboada, Thomas Morris	2011	27
18	Tolerability, efficacy and pharmacokinetics of bicalutamide 300 mg, 450 mg or 600 mg as monotherapy for patients with locally advanced or metastatic prostate cancer, compared with castration British Journal of Urology ·C. Tyrrell, Peter Iversen, Teuvo L.J. Tammela, John Anderson, Thomas Björk, Amir V. Kaisary, Thomas Morris	2006	27
19	A phase I study of zibotentan (ZD4054) in patients with metastatic, castrate-resistant prostate cancer Investigational New Drugs ·William R. Schelman, Glenn Liu, George Wilding, Thomas Morris, De Phung, Robert Dreicer	2009	24
20	Evaluation of Host Serum Protein Biomarkers of Tuberculosis in sub-Saharan Africa Frontiers in Immunology ·Thomas Morris, Clive Hoggart, Novel N. Chegou, Martin Kidd, Tolu Oni, René Goliath, Katalin A. Wilkinson, Hazel M. Dockrell, Lifted Sichali, Louis Banda, Amelia C. Crampin, Neil French, Gerhard Walzl, Michael Levin, Robert J. Wilkinson, Melissa Shea Hamilton	2021	24

About Thomas Morris

Thomas Morris is a scholar working on Pulmonary and Respiratory Medicine, Oncology, Endocrinology, Diabetes and Metabolism, Cancer Research and Radiology, Nuclear Medicine and Imaging, having authored 59 papers that have together received 1.6k indexed citations. Recurring topics across this work include Prostate Cancer Treatment and Research (35 papers), Prostate Cancer Diagnosis and Treatment (13 papers), Radiopharmaceutical Chemistry and Applications (11 papers), Hormonal and reproductive studies (10 papers), Bone health and treatments (9 papers), Cancer, Lipids, and Metabolism (7 papers), Cancer Treatment and Pharmacology (5 papers) and PI3K/AKT/mTOR signaling in cancer (5 papers). The work is most often cited by research in Pulmonary and Respiratory Medicine (1.1k citations), Endocrinology, Diabetes and Metabolism (295 citations), Cancer Research (235 citations), Oncology (338 citations) and Radiology, Nuclear Medicine and Imaging (227 citations). Thomas Morris has collaborated with scholars based in United Kingdom, United States and Denmark. Frequent co-authors include Peter Iversen, J. Armstrong, Manfred P. Wirth, David G. McLeod, William A. See, Stuart McIntosh, Kristine Pemberton, Karim Fizazi, Martin Gleave and De Phung. Their work appears in journals such as Prostate Cancer and Prostatic Diseases, Journal of Clinical Oncology, British Journal of Urology, European Urology and Cancer Chemotherapy and Pharmacology.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact